Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Despite concerns that recombinant human Activated Protein C (rhAPC) is associated with an increased risk of bleeding, the FDA failed to list several of the bleeding-related exclusion criteria used in the PROWESS trial as contraindications to use of this agent.

Should Patients at Increased Risk of Bleeding Receive Activated Protein C?